Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial
详细信息 查看全文
- 作者：F. Longo-Muñoz ; G. Argiles ; J. Tabernero…
- 关键词：TAS ; 102 ; Metastatic colorectal cancer ; Trifluridine ; Tipiracil hydrochloride ; Fluoropyrimidine ; Spain
- 刊名：Clinical and Translational Oncology
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：19
- 期：2
- 页码：227-235
- 全文大小：1023KB
- 刊物主题：Oncology;
- 出版者：Springer International Publishing
- ISSN：1699-3055
- 卷排序：19
文摘
PurposeTAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.